Evidence map›Paper›PMID 40785711›Full record

ArticleIranian journal of microbiology2025

Eradication of

Yousra Sbibih, Abderrazak Saddari, Ilham Alla, Said Ezrari, Elmostapha Benaissa, Yassine Ben Lahlou, Mostafa Elouennass, Adil Maleb

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yousra SbibihLaboratory of Microbiology, Faculty of Medicine and Pharmacy, University Mohammed the First, Oujda, Morocco.
Abderrazak SaddariLaboratory of Microbiology, Faculty of Medicine and Pharmacy, University Mohammed the First, Oujda, Morocco.
Ilham AllaLaboratory of Microbiology, Faculty of Medicine and Pharmacy, University Mohammed the First, Oujda, Morocco.
Said EzrariLaboratory of Microbiology, Faculty of Medicine and Pharmacy, University Mohammed the First, Oujda, Morocco.
Elmostapha BenaissaDepartment of Bacteriology, Mohammed V Teaching Military Hospital, Rabat, Morocco.
Yassine Ben LahlouDepartment of Bacteriology, Mohammed V Teaching Military Hospital, Rabat, Morocco.
Mostafa ElouennassDepartment of Bacteriology, Mohammed V Teaching Military Hospital, Rabat, Morocco.
Adil MalebLaboratory of Microbiology, Faculty of Medicine and Pharmacy, University Mohammed the First, Oujda, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Materials and Methods: This 13-month retrospective descriptive study was conducted at the Microbiology Laboratory of Mohammed VI University Hospital in Oujda, Morocco, to evaluate patients suspected of Results: A total of 190 patients were included, with an overall eradication rate of 73%. Three therapeutic protocols were tested, and bismuth concomitant therapy showed the highest eradication rate at 82%, outperforming the other regimens. Conclusion: These findings highlight the importance of combining antimicrobial agents with antisecretory treatments to enhance eradication outcomes. The study also emphasizes the need for novel treatment strategies, particularly in light of rising antibiotic resistance. Vonoprazan-based regimens appear to offer a promising alternative, especially in the absence of antibiotic sensitivity testing. Future research should focus on optimizing treatment protocols while preserving beneficial gut flora.

Indexed as

Antibiotic resistanceAntimicrobial therapyEradicationHelicobacter pyloriTreatment protocolsUrea breath test

Identifiers

PMID40785711
PMCPMC12331460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.